Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978591 | 0.88 | DRD2 (0.61) | CYP3A4DRD2DRD1TAAR1MGLL | |
| SCHEMBL29616870 | 0.88 | DRD2 (0.61) | CYP3A4DRD2DRD1TAAR1MGLL | |
| SCHEMBL81571 | 0.85 | ACMSD (0.49) | ACMSDCYP4F2CYP4A11 | |
| SCHEMBL3231456 | 0.83 | ACMSD (0.47) | ACMSDCYP4F2CYP4A11 | |
| SCHEMBL3172595 | 0.82 | DRD2 (0.59) | DRD2DRD1TAAR1MGLLCHRM2 | |
| SCHEMBL21396987 | 0.81 | MGLL (0.60) | DRD2DRD1TAAR1MGLLCHRM2 | |
| SCHEMBL4437687 | 0.81 | MGLL (0.60) | DRD2DRD1TAAR1MGLLCHRM2 | |
| SCHEMBL5661640 | 0.81 | MGLL (0.60) | DRD2DRD1TAAR1MGLLCHRM2 | |
| SCHEMBL8053899 | 0.81 | MGLL (0.60) | DRD2DRD1TAAR1MGLLCHRM2 | |
| SCHEMBL14568511 | 0.80 | HSD17B1 (0.60) | HSD17B1HSD17B2CYP3A4CYP2C9GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2181174-A1 | LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | KLK3, LPXN, PSAP | HSD17B1 2575/4885HSD17B2 2137/4885CYP3A4 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.